Zurich Insurance Group Ltd FI Reduces Stock Position in Boston Scientific Corporation $BSX

Key Points

• Zurich Insurance Group Ltd FI reduced its stake in Boston Scientific Corporation by 21.6%, now holding 1,380,806 shares worth approximately $139.3 million.
• Boston Scientific reported earnings of $0.75 per share, surpassing analyst expectations, with revenue reaching $5.06 billion for the last quarter, a 22.8% increase year-over-year.
• Institutional investors own 89.07% of Boston Scientific's stocks, indicating strong interest from large entities, while several firms have adjusted their price targets, suggesting an upward outlook for the stock.

Zurich Insurance Group Ltd FI lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 21.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,380,806 shares of the medical equipment provider's stock after selling 381,406 shares during the quarter. Boston Scientific comprises 1.1% of Zurich Insurance Group Ltd FI's portfolio, making the stock its 18th biggest holding. Zurich Insurance Group Ltd FI owned 0.09% of Boston Scientific worth $139,296,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. 1248 Management LLC bought a new position in shares of Boston Scientific in the first quarter worth about $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific during the 1st quarter valued at approximately $27,000. Investment Management Corp VA ADV bought a new stake in Boston Scientific during the 4th quarter valued at approximately $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the 4th quarter valued at approximately $26,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the 4th quarter valued at approximately $31,000. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on BSX shares. UBS Group lifted their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Raymond James Financial lifted their target price on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Finally, Leerink Partners assumed coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Price Performance

NYSE BSX traded down $1.63 during trading on Friday, hitting $102.71. 10,541,837 shares of the stock traded hands, compared to its average volume of 6,378,869. The company has a market capitalization of $152.19 billion, a P/E ratio of 61.14, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. The firm has a 50-day simple moving average of $104.86 and a 200-day simple moving average of $102.27. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.